EFPIA Sees Room For Improved Japan Innovation Rewards
This article was originally published in PharmAsia News
Executive Summary
Backed up by a new simulation of the development of the Japanese pharma market over the next decade, the European industry federation EFPIA says there is room within the reimbursement system to award higher prices to innovative drugs, with the costs to be more than balanced out by savings from rapidly rising generic use.